AbbVie Inc. (ABBV) Shares Bought by Zacks Investment Management

Zacks Investment Management boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 1.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 574,748 shares of the company’s stock after purchasing an additional 9,771 shares during the quarter. AbbVie comprises approximately 1.0% of Zacks Investment Management’s portfolio, making the stock its 28th biggest position. Zacks Investment Management’s holdings in AbbVie were worth $41,675,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ABBV. Acropolis Investment Management LLC acquired a new stake in shares of AbbVie in the second quarter valued at approximately $106,000. Franklin Parlapiano Turner & Welch LLC acquired a new stake in shares of AbbVie in the first quarter valued at approximately $108,000. Hudock Capital Group LLC boosted its holdings in shares of AbbVie by 109.5% in the second quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock valued at $111,000 after acquiring an additional 806 shares during the period. Ffcm LLC boosted its holdings in shares of AbbVie by 167.2% in the second quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after acquiring an additional 963 shares during the period. Finally, BDO Wealth Advisors LLC acquired a new stake in shares of AbbVie in the second quarter valued at approximately $115,000. 69.32% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have recently weighed in on the company. Leerink Swann set a $106.00 price objective on AbbVie and gave the company a “buy” rating in a report on Tuesday. BMO Capital Markets set a $84.00 price objective on AbbVie and gave the company a “hold” rating in a report on Monday, December 4th. ValuEngine downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a report on Friday, December 1st. Societe Generale increased their price objective on AbbVie in a report on Tuesday, November 21st. Finally, BidaskClub raised AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 11th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $97.96.

Shares of AbbVie Inc. (NYSE:ABBV) opened at $95.95 on Friday. AbbVie Inc. has a 52 week low of $59.27 and a 52 week high of $98.52. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08. The company has a market capitalization of $150,447.55, a P/E ratio of 17.75, a PEG ratio of 1.31 and a beta of 1.52.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 27th. The company reported $1.41 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.02. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The business had revenue of $7 billion during the quarter, compared to analysts’ expectations of $7 billion. During the same quarter in the prior year, the business earned $1.21 earnings per share. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. research analysts forecast that AbbVie Inc. will post 5.55 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 2.96%. The ex-dividend date of this dividend is Thursday, January 11th. This is a boost from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio is 62.29%.

In other AbbVie news, VP Robert A. Michael sold 6,699 shares of the stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $88.00, for a total value of $589,512.00. Following the completion of the transaction, the vice president now owns 10,007 shares in the company, valued at $880,616. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Azita Saleki-Gerhardt sold 8,300 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $85.02, for a total value of $705,666.00. Following the completion of the transaction, the senior vice president now owns 93,099 shares of the company’s stock, valued at approximately $7,915,276.98. The disclosure for this sale can be found here. Insiders have sold 277,125 shares of company stock valued at $25,891,756 in the last 90 days. Company insiders own 0.23% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Week Herald and is the property of of Week Herald. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://weekherald.com/2017/12/09/abbvie-inc-abbv-shares-bought-by-zacks-investment-management.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply